Natus Medical Inc  

(Public, NASDAQ:BABY)   Watch this stock  
Find more results for BABY
39.13
+1.05 (2.76%)
Mar 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 37.86 - 39.28
52 week 21.54 - 39.93
Open 38.00
Vol / Avg. 239,449.00/266,596.00
Mkt cap 1.28B
P/E 39.40
Div/yield     -
EPS 0.99
Shares 32.70M
Beta 0.90
Inst. own 90%
Jun 1, 2015
Natus Medical Incorporated Annual Shareholder Meeting (Estimated) Add to calendar
Apr 21, 2015
Q1 2015 Natus Medical Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 9, 2015
Natus Medical Inc at ROTH Conference
Mar 2, 2015
Natus Medical Inc at Raymond James Institutional Investors Conference
Jan 28, 2015
Q4 2014 Natus Medical Inc Earnings Call - Webcast
Jan 28, 2015
Q4 2014 Natus Medical Inc Earnings Release
Jan 15, 2015
Natus Medical Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 11.38% 9.13%
Operating margin 15.00% 12.89%
EBITD margin - 17.48%
Return on average assets 10.10% 7.52%
Return on average equity 12.54% 9.83%
Employees 948 -
CDP Score - -

Address

6701 Koll Center Parkway, Suite 120
PLEASANTON, CA 94566
United States - Map
+1-925-2236700 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Natus Medical Incorporated is a provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. The Company�s product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products, such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn�s environment, and software systems for managing and tracking disorders and diseases for public health laboratories. Natus categorizes its products into two categories: neurology and newborn care.

Officers and directors

Robert A. Gunst Independent Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
James B. Hawkins President, Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jonathan A. Kennedy Chief Financial Officer, Senior Vice President
Age: 44
Bio & Compensation  - Reuters
Austin F. Noll III Vice President and General Manager - Neurology Strategic Business Unit
Age: 48
Bio & Compensation  - Reuters
Kenneth M. Traverso Vice President, General Manager - Newborn Care Strategic Business Unit
Age: 54
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Ajay A. Bhave Vice President - Global Engineering
Age: 58
Bio & Compensation  - Reuters
D. Christopher Chung M.D. Vice President - Medical Affairs, Quality & Regulatory
Age: 51
Bio & Compensation  - Reuters
Doris E. Engibous Independent Director
Age: 59
Bio & Compensation  - Reuters
Kenneth E. Ludlum Independent Director
Age: 60
Bio & Compensation  - Reuters
Will M. Moore Jr. Independent Director
Age: 65
Bio & Compensation  - Reuters